Delivery Order SPE2DB24D1021-SPE2DB25FEZED
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Actemra 162 mg/0.9 mL syringes valued at $11,411.43 under a firm fixed-price contract. The delivery order is non-set-aside and carries an ultimate completion date of September 4, 2025, with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,287.88 to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Actemra 162 mg/0.9 ml syringes. This is a firm fixed price delivery order with a completion date of September 2, 2025, with no set-aside designation applied. The contract represents a competitive award under DLA's broader pharmaceutical supply framework, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $19,792.71 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 mL syringes. This firm fixed price, competitively awarded contract was executed on September 10, 2025, with an ultimate completion date of September 11, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a delivery order valued at $2,877.84 to AmerisourceBergen Drug Corp on June 16, 2025, for the supply of Actemra 162 mg/0.9 mL syringes. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and requires completion by June 17, 2025, with performance taking place at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a $3,729.39 delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Actemra 200 mg/10 mL vials. The contract, which is a firm fixed price delivery order with an ultimate completion date of August 20, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). This award was made through open competition with no set-aside designation, reflecting...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Actemra 162 mg/0.9 mL syringes. This is a non-set-aside, competitively awarded contract with a firm fixed price ceiling value of $9,793.69 and a completion date of August 15, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Actemra 162 mg/0.9 mL syringes with a ceiling value of $16,453.58. This is a firm fixed-price delivery order with an ultimate completion date of September 11, 2025, and no set-aside designation was used in the award. The product will be delivered to the company's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $2,287.88 to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Actemra 162 mg/0.9 mL syringes. The contract reflects a firm fixed price arrangement with an ultimate completion date of August 20, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded without set-aside designation, consistent with the vendor's track...
- The Defense Logistics Agency awarded a $27,454.56 delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Actemra 162 mg/0.9 mL syringes. The contract employs firm fixed price terms with an ultimate completion date of September 16, 2025, and utilizes no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $10,722.90 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 ml syringes on June 16, 2025, with an ultimate completion date of June 17, 2025. This firm fixed price, competitively awarded contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- SPE2DB24D1021Indefinite Delivery Contract
- SPE2DB24D1021-SPE2DB25FEZEDDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,158.38 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 mL syringes. The contract, issued on August 1, 2025, with an ultimate completion date of August 4, 2025, utilizes firm fixed pricing with no set-aside designation, indicating competitive award. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen supplies a comprehensive portfolio of pharmaceutical products and medical supplies to support military and veteran healthcare systems. The company's extensive federal contract history with DLA demonstrates its capability to fulfill medical procurement requirements across multiple therapeutic domains. This specific delivery order for Actemra, a biologic medication used in rheumatoid arthritis treatment, exemplifies the company's role in providing specialty medications to Defense Health Agency and other federal healthcare customers through DLA's medical supply chain infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.2k | 8/1/25 |